Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate SalePRNewsWire • 12/20/23
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache SocietyGlobeNewsWire • 06/15/23
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/23
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023GlobeNewsWire • 05/05/23
Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine MedicationsGlobeNewsWire • 04/26/23
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of DirectorsGlobeNewsWire • 04/12/23
Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/24/23
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/24/23
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023GlobeNewsWire • 03/17/23
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in MarchGlobeNewsWire • 03/03/23
Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial OpportunityGlobeNewsWire • 02/22/23
Impel Pharmaceuticals Inc. (IMPL) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/14/22
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/14/22
Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology DayGlobeNewsWire • 11/08/22
Impel Pharmaceuticals, Inc. (IMPL) CEO Adrian Adams on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/15/22
Impel Pharmaceuticals Inc. (IMPL) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/15/22
Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/15/22
Impel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare ConferenceGlobeNewsWire • 08/02/22
Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)GlobeNewsWire • 07/19/22